These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16505459)

  • 1. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies.
    Papanikolaou PN; Christidi GD; Ioannidis JP
    CMAJ; 2006 Feb; 174(5):635-41. PubMed ID: 16505459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials.
    Papanikolaou PN; Ioannidis JP
    Am J Med; 2004 Oct; 117(8):582-9. PubMed ID: 15465507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence based evaluation of immuno-coagulatory interventions in critical care.
    Afshari A
    Dan Med Bull; 2011 Sep; 58(9):B4316. PubMed ID: 21893014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program.
    Chou R; Aronson N; Atkins D; Ismaila AS; Santaguida P; Smith DH; Whitlock E; Wilt TJ; Moher D
    J Clin Epidemiol; 2010 May; 63(5):502-12. PubMed ID: 18823754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to apply results from randomized trials and systematic reviews to individual patient care.
    Hodson EM; Craig JC
    Nephrology (Carlton); 2010 Apr; 15(3):277-80. PubMed ID: 20470294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of evidence of treatment effects in randomized and nonrandomized studies.
    Ioannidis JP; Haidich AB; Pappa M; Pantazis N; Kokori SI; Tektonidou MG; Contopoulos-Ioannidis DG; Lau J
    JAMA; 2001 Aug; 286(7):821-30. PubMed ID: 11497536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?
    Baker SG; Kramer BS; Corle D
    BMC Med Res Methodol; 2004 Oct; 4():24. PubMed ID: 15461821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting of harm in randomized controlled trials published in the urological literature.
    Breau RH; Gaboury I; Scales CD; Fesperman SF; Watterson JD; Dahm P
    J Urol; 2010 May; 183(5):1693-7. PubMed ID: 20299044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative rates of harms in randomized trials from more developed versus less developed countries may be different.
    Contopoulos-Ioannidis D; Tseretopoulou X; Ancker M; Walterspiel JN; Panagiotou OA; Maldonado Y; Ioannidis JP
    J Clin Epidemiol; 2016 Oct; 78():10-21. PubMed ID: 27063207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical versus surgical treatment of type 2 diabetes: the search for level 1 evidence.
    Shukla AP; Moreira M; Dakin G; Pomp A; Brillon D; Sinha N; Strain GW; Lebovitz H; Rubino F
    Surg Obes Relat Dis; 2012; 8(4):476-82. PubMed ID: 22551575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementarity comes of age.
    Black N
    Transplantation; 2008 Jul; 86(1):28-9. PubMed ID: 18622273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balancing benefits and harms in health care: observational data on harm should complement systematic reviews of benefit.
    Vandenbroucke JP
    BMJ; 2003 Sep; 327(7417):750. PubMed ID: 14512491
    [No Abstract]   [Full Text] [Related]  

  • 14. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized and nonrandomized studies: complementary or competing?
    Pandis N; Tu YK; Fleming PS; Polychronopoulou A
    Am J Orthod Dentofacial Orthop; 2014 Nov; 146(5):633-40. PubMed ID: 25439214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the best evidence for determining harms of medical treatment?
    Vandenbroucke JP
    CMAJ; 2006 Feb; 174(5):645-6. PubMed ID: 16505461
    [No Abstract]   [Full Text] [Related]  

  • 17. The renaissance of field experimentation in evaluating interventions.
    Shadish WR; Cook TD
    Annu Rev Psychol; 2009; 60():607-29. PubMed ID: 18616391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval.
    Djulbegovic B; Glasziou P; Klocksieben FA; Reljic T; VanDenBergh M; Mhaskar R; Ioannidis JPA; Chalmers I
    J Clin Epidemiol; 2018 Jun; 98():24-32. PubMed ID: 29432860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of randomization in clinical studies: myths and beliefs.
    Abel U; Koch A
    J Clin Epidemiol; 1999 Jun; 52(6):487-97. PubMed ID: 10408986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing benefits and harms in health care: observational data on harm are already included in systematic reviews.
    Jefferson T; Demicheli V
    BMJ; 2003 Sep; 327(7417):750. PubMed ID: 14512492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.